News Contact Us

Roche’s Tecentriq bags priority review for treating advanced NSCLC

Author : Pankaj Singh | Published Date : 2020-02-20 

Swiss multinational pharmaceutical company, Roche has recently revealed that the U.S. FDA has acknowledged its sBLA (supplemental Biologics License Application) and approved Priority Review for Tecentriq® (atezolizumab) as an initial monotherapy for patients suffering from advanced NSCLC (non-squamous and squamous non-small cell lung cancer) without ALK mutations with elevated PD-L1 expression or EGFR. Reportedly, the FDA is anticipated to come to a decision by June 19, 2020.

According to reliable sources, this sBLA is centered around the findings from the Phase III IMpower110 trial, which demonstrated that Tecentriq monotherapy enhanced OS (overall survival) by 7.1 months when equated to chemotherapy in patients with extreme PD-L1 expression. Tecentriq’s safety profile seemed to be coherent with its known safety profile, with no additional safety signals being detected.

Speaking on the move, Levi Garraway, M.D., Ph.D., Head of Global Product Development and Chief Medical Officer, Roche, said that revisiting the IMpower110 trial, Tecentriq solely established a noteworthy improvement in OS when compared to chemotherapy for newly diagnosed NSCLC patients.

Additionally, the company is closely working with the FDA to release its chemotherapy-free alternative for all NSCLC patients as soon as possible.

Prior to this news, Roche had made headlines when the China National Medical Products Administration (NMPA) granted approval Tecentriq®, in association with chemotherapy ( etoposide and carboplatin), for the initial therapy of patients with ES-SCLC (extensive-stage small cell lung cancer).

Commenting on which, Garraway added that small cell lung cancer is a crucial segment with huge unmet needs in China. Besides, there haven’t been any major advances in this sector until now.

With this consent, Tecentriq would become the first-ever cancer immunotherapy to be accessible in China for the first-line therapy of ES-SCLC. This would come as an important and swift leap for patients, in terms of medical progression, who suffer from this chronic disease.

Source Credit: http://www.globenewswire.com/news-release/2020/02/19/1986747/0/en/FDA-grants-priority-review-to-Roche-s-Tecentriq-monotherapy-as-first-line-treatment-of-certain-people-with-advanced-non-small-cell-lung-cancer.html

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Britain nears USD 625 million COVID-19 vaccine deals with Sanofi/GSK

Published Date: 2020-07-06         Author: Pankaj Singh

With over 100 vaccines are being tested and developed to stop the spread of COVID-19, it seems that governments worldwide are racing to secure supplies of vaccines even before their efficiency is proven. As per the latest news, Britain government is close to a USD 625 million supply deals with Sanof... Read More

ByteDance could lose $6 billion following recent TikTok ban in India

Published Date: 2020-07-03         Author: Pankaj Singh

The latest decision taken by the Government of India to ban 59 Chinese smartphone apps is trending worldwide, especially across China. As per a report by China’s Global Times, ByteDance, the parent firm of Helo and TikTok, is likely to incur a loss of about $6 billion after this imposed ban by... Read More

Oyo suspends MGB contracts for property owners due to reduced revenues

Published Date: 2020-07-01         Author: Pankaj Singh

The adverse impact of COVID-19 pandemic is becoming more and more evident across the world. It is being speculated that  nothing of this magnitude has been observed for more than 100 years since the 1918 Spanish Flu pandemic. Till now, over ten million people have been infected in over 200 nati... Read More

© 2020 Fractovia. All Rights Reserved